These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16675713)

  • 1. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
    Sanchez-Gonzalez B; Yang H; Bueso-Ramos C; Hoshino K; Quintas-Cardama A; Richon VM; Garcia-Manero G
    Blood; 2006 Aug; 108(4):1174-82. PubMed ID: 16675713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
    Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
    Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
    Kadia TM; Yang H; Ferrajoli A; Maddipotti S; Schroeder C; Madden TL; Holleran JL; Egorin MJ; Ravandi F; Thomas DA; Newsome W; Sanchez-Gonzalez B; Zwiebel JA; Espinoza-Delgado I; Kantarjian HM; Garcia-Manero G
    Br J Haematol; 2010 Jul; 150(1):72-82. PubMed ID: 20456355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors.
    Halsall J; Gupta V; O'Neill LP; Turner BM; Nightingale KP
    PLoS One; 2012; 7(3):e33453. PubMed ID: 22479401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
    Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
    Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
    Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
    Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
    Wei Y; Kadia T; Tong W; Zhang M; Jia Y; Yang H; Hu Y; Tambaro FP; Viallet J; O'Brien S; Garcia-Manero G
    Clin Cancer Res; 2010 Aug; 16(15):3923-32. PubMed ID: 20538760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
    Takai N; Desmond JC; Kumagai T; Gui D; Said JW; Whittaker S; Miyakawa I; Koeffler HP
    Clin Cancer Res; 2004 Feb; 10(3):1141-9. PubMed ID: 14871994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
    Munshi A; Tanaka T; Hobbs ML; Tucker SL; Richon VM; Meyn RE
    Mol Cancer Ther; 2006 Aug; 5(8):1967-74. PubMed ID: 16928817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
    Aron JL; Parthun MR; Marcucci G; Kitada S; Mone AP; Davis ME; Shen T; Murphy T; Wickham J; Kanakry C; Lucas DM; Reed JC; Grever MR; Byrd JC
    Blood; 2003 Jul; 102(2):652-8. PubMed ID: 12649137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
    Batova A; Shao LE; Diccianni MB; Yu AL; Tanaka T; Rephaeli A; Nudelman A; Yu J
    Blood; 2002 Nov; 100(9):3319-24. PubMed ID: 12384433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
    Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
    Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers.
    Vulcano F; Ciccarelli C; Mattia G; Marampon F; Giampiero M; Milazzo L; Pascuccio M; Zani BM; Giampaolo A; Hassan HJ
    Exp Cell Res; 2006 May; 312(9):1590-7. PubMed ID: 16739251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM; Sandhoff TW; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.